PRAT4B_Cnpy4 Activators

The class of chemicals listed as CNPY4 Activators includes compounds that indirectly influence CNPY4 through their effects on the FGF signaling pathway. These compounds are not direct activators of CNPY4 but may impact its function by modulating the cellular environment and processes related to FGF signaling. Compounds such as Basic Fibroblast Growth Factor (bFGF) and FGF-2 play direct roles in FGF signaling, a pathway where CNPY4 is implicated. By enhancing FGF signaling, these growth factors could indirectly affect CNPY4 function.Small molecule inhibitors targeting FGF receptors, such as PD173074, SU5402, Dovitinib, Nintedanib, and AZD4547, can modulate the FGF signaling pathway. Although these inhibitors primarily function to diminish FGF signaling, their use in biological systems can shed light on the role of CNPY4 in this pathway.

Multi-targeted tyrosine kinase inhibitors like Lenvatinib, Ponatinib, and Lucitanib, which have activity against FGF receptors, might indirectly influence CNPY4 by altering FGF signaling dynamics. Similarly, selective FGFR inhibitors such as Erdafitinib and BGJ398 (Infigratinib) may impact CNPY4 function indirectly through their modulation of FGF signaling.Overall, while these compounds do not specifically target CNPY4, their involvement in FGF signaling pathways suggests they could have an indirect impact on the functionality of CNPY4. Understanding these indirect influences is important for exploring the broader context of CNPY4's role in physiological and pathological conditions related to FGF signaling.